Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

N/AActive Not RecruitingNCT05639556

Jaeb Center for Health Research300 enrolled

Overview

The goal of the study is to examine multiple markers of anthropometrics, body composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry (DXA) output, which is considered the current clinical gold-standard tool to measure body composition. The result of this study will provide detailed data regarding the nutrition and body composition within this Cystic Fibrosis population and also provide a baseline evaluation for use of these biomarkers in the future studies including evaluation of nutritional intervention. Further, the study will also include psychosocial and other patient-reported outcomes and medical contributors to understand their contributions to the nutritional failure in the adult advanced lung disease population. Finally, the study will evaluate both established and emerging nutritional and body composition parameters and link them to clinical outcomes in adults with CF across the spectrum of pulmonary function.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Cystic Fibrosis

Interventions

BMI and lean mass index from DXADIAGNOSTIC_TEST

Estimate and compare correlation between lean mass index from DXA and BMI

Anthropometric MeasurementsDIAGNOSTIC_TEST

Skinfold will be assessed with calipers. Circumference will be measured with a tape measure.

Hand-grip strengthDIAGNOSTIC_TEST

A small, handheld dynamometer will be used to measure grip strength, a measure of function, on each hand.

Six-minute walk TestDIAGNOSTIC_TEST

This will be another functional assessment of fitness. Participants will be asked to walk at their normal pace for 6 minutes.The total distance walked in that time will be measured.

Sit-to-Stand TestDIAGNOSTIC_TEST

This will be used as a functional assessment of fitness and lower extremity strength. Participants will start seated on a chair and be asked to complete as many sit-to-stand repetitions without using their arms for one minute.

Short physical performance battery (SPPB)DIAGNOSTIC_TEST

This is an assessment of frailty. The test is completed in approximately 8 minutes. The test consists of 3 assessments: 1) Balance tests where the participant stands and tries to balance with their feet in various positions for 10 seconds each without assistance (side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3) Chair-stand tests (single chair stand, 5 chair stands).

BIA Sub-studyDIAGNOSTIC_TEST

A minimum of 50 individuals will be enrolled. Body composition will be assessed at each study visit using study bioelectrical impendence analysis (BIA).

Accelerometry to assess physical activityDIAGNOSTIC_TEST

Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the baseline study visit and asked to wear it continuously for at least 3-10 days (two weekdays, one weekend day). Approximately every 3 months, the participant will be asked to again wear the accelerometer. Participants will be able to keep their accelerometers.

Gastrointestinal (GI) and nutrition questionnaires:OTHER

Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored Patient-Generated Subjective Global Assessment (PG-SGA).

Psychosocial questionnaire: PHQ-8OTHER

This is an 8-item scale that measures depressive symptoms over the past two weeks.

Psychosocial questionnaire: GAD-7OTHER

This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not at all to nearly every day.

Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)OTHER

This is a 15-item scale that assesses the degree to which participants' motivation is autonomous or self-regulated.

Psychosocial questionnaire: CF Fatalism ScaleOTHER

The CF Fatalism Scale measures the belief in a lack of personal power or control over one's future and has 13 items.

Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)OTHER

The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of self-evaluations of one's body or appearance.

12-month QuestionnaireOTHER

A short questionnaire designed to explore participants' perspectives of the acceptability and feasibility of nutritional assessments used in STRONG-CF will be given to all study participants at the end of the study.

Oral glucose tolerance testing (OGTT)OTHER

For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and 12-months with samples analyzed at the central lab.

Continuous glucose monitoring (CGM)DEVICE

Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to collect comprehensive glucose data.

Chest CT scans (When available within the past 6 months in medical records)DIAGNOSTIC_TEST

Standard of Care chest CT images will be drawn from the medical record, as available, from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to account for possible illness occurring at the time of scanning. Quantitative assessment of the pectoralis muscle area will be performed on the first single axial image above the aortic arch. Any additional standard of care chest CT's that are performed while the participant is enrolled in the study will also be collected and have a quantitative assessment of the pectoralis muscle performed.

Hologic Dual X-Ray Absorptiometry (DXA)DIAGNOSTIC_TEST

DXA measurements for whole body, total hip and lumbar spine will be acquired using the Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will be used to estimate total and regional body composition, which will include body fat and lean body mass. This will be used as the gold standard from which to validate BIA and MAMC.

Ultrasound Sub-study of assessment of appendage muscles using ultrasoundDIAGNOSTIC_TEST

A minimum of 50 individuals will be enrolled. At each study visit, participants will undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the biceps and quadriceps on each (left and right) side of the body (4 total areas). These measurements will be obtained in triplicate for each patient.

Psychosocial questionnaire: Hunger Vital Sign questionnaireDIAGNOSTIC_TEST

Screening tool for identifying households at risk of food insecurity and poor health outcomes linked to food insecurity with 3-items over the last 12 months.

Respiratory symptom questionnaire: CRISSOTHER

Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom questionnaire covering the last 24-hours.

SpirometryDIAGNOSTIC_TEST

Spirometry will be performed in accordance with the current American Thoracic Society recommendations for the performance and interpretation of tests.

Psychosocial questionnaire: Additional Health QuestionnaireOTHER

Single question over the last 3 months/90 days about cannabis use for GI problems and appetite. The clinical sites will not see the responses to this question. It will be completed by the participant online either during the study visit or at home.

CF Management QuestionnaireOTHER

Assessment of prior 12-month management of cystic fibrosis, including treatments, medication intake and hospitalizations. This questionnaire will only be completed at 24- and 36- month visits.

Food Frequency QuestionnaireOTHER

Assessment of prior 12-month nutritional intake being completed at Baseline (no later than 6-month visit) and 12-month visit.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Cohort 1: Participants are eligible if their percentage of predicated forced expiratory volume in 1 second (ppFEV1) is \<70% during the 12 months prior to enrollment (\>50% of measurements, eliminating periods of exacerbation) * Cohort 2: Participants are eligible if their percentage of predicted forced expiratory volume in 1 second (ppFEV1) is 70% or greater during the 12 months prior to enrollment (\>50% of measurements, eliminating periods of exacerbation). * Both cohorts match by age, gender, race and CFTR genotype severity. Exclusion Criteria: * No prior solid organ transplantation * No initiation of an investigation drug within 28 days prior to and including Baseline Visit. * No initiation of new chronic therapy (e.g., ibuprofen, azithromycin, inhaled tobramycin, Cayston, CFTR modulator, etc.) within 28 days prior to and including Baseline visit. * No acute use of antibiotics (oral, inhaled or IV) or acute use of systemic corticosteroids for respiratory tract symptoms within 14 days prior to and including Baseline visit. * For the BIA sub-study - Individuals with an implanted pacemaker will be excluded. * No initiation of a drug for weight loss (such as a GLP-1 receptor agonist) or bariatric surgery within 6-months prior to and including the Baseline visit. * Patients with continued rapid change or extreme GI symptoms related to weight loss therapy should be excluded at the discretion of the study investigator.

Locations (23)

University of Arizona

Tucson, Arizona, United States

University of Arkansas for Medical Sciences (UAMS)

Little Rock, Arkansas, United States

Emory

Atlanta, Georgia, United States

Northwestern University

Chicago, Illinois, United States

University of Iowa

Iowa City, Iowa, United States

University of Kentucky

Lexington, Kentucky, United States

Tulane University

New Orleans, Louisiana, United States

John Hopkins University

Baltimore, Maryland, United States

Massachusetts General Hospital (MGH)

Boston, Massachusetts, United States

Boston Children's Hospital and Brigham and Women's CF Center

Boston, Massachusetts, United States

...and 13 more locations